Physician profile
Robert W Barish
NPI 1538197165
$4,653.50
in general payments reported to CMS, 2019-2025
30 companies · $2,013 in 2025
The $2,013 reported for 2025 was more than what 79% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $590 · 2020: $586 · 2021: $312 · 2022: $297 · 2023: $67.39 · 2024: $789 · 2025: $2,013.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,985 · Travel and Lodging: $852 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,985.25 |
| Travel and Lodging | $851.74 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $1,345.07 | 2024-2025 | Rezdiffra |
| Abbvie INC. | $1,233.50 | 2019-2025 | |
| Boston Scientific Corporation | $483.37 | 2020-2025 | Watchman Flx |
| Novo Nordisk INC | $306.46 | 2021-2025 | Wegovy |
| Ipsen Biopharmaceuticals, INC | $216.60 | 2024 | Iqirvo |
| Gilead Sciences, INC. | $179.24 | 2019-2023 | |
| Medtronic, INC. | $139.99 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $136.25 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $112.06 | 2024 | Voquezna |
| Lilly USA, LLC | $82.49 | 2024 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $75.20 | 2022 | |
| Intercept Pharmaceuticals, INC. | $71.17 | 2019-2020 | |
| Ironwood Pharmaceuticals, INC | $48.54 | 2019-2020 | |
| Pfizer INC. | $45.67 | 2019 | |
| Nestle Healthcare Nutrition INC. | $34.56 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $33.30 | 2019 | |
| Beigene USA, INC. | $29.85 | 2025 | Tevimbra, Brukinsa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.45 | 2021 | |
| Merck Sharp & Dohme LLC | $17.88 | 2019 | |
| Shionogi INC | $14.29 | 2019 | |
| Redhill Biopharma INC. | $13.40 | 2020 | |
| Pharming Healthcare, INC. | $13.16 | 2020 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.